Compounded Medication for Eczema and Psoriasis: When Commercial Treatments Stop Working in 2026

Introduction: When Standard Treatments Are No Longer Enough

For millions of people living with eczema or psoriasis, the treatment journey often feels like an exhausting loop. A tube of steroid cream works for a few weeks, then stops. A prescription solution burns on application. An over-the-counter moisturizer triggers a reaction instead of soothing one. Patients cycle through product after product, only to be told they have “tried everything,” when in reality they have only tried the same standardized formulations in slightly different packaging.

The scale of this frustration is significant. Atopic dermatitis (eczema) affects up to 20% of children and roughly 10% of adults in the United States, ranking first among skin diseases as measured by disability-adjusted life-years (JAAD, 2026). Psoriasis affects about 3% of US adults, roughly 7.5 million people, and global prevalence has climbed 86% between 1990 and 2021 (NIH/PMC, 2025).

When commercial, one-size-fits-all topicals fail, compounded medication for eczema and psoriasis offers a clinically grounded, patient-specific alternative. This is not a fringe last resort; it is a precision tool. This article explores why commercial treatments fail, the key ingredients used in compounded dermatology formulations, the emerging role of Low Dose Naltrexone (LDN), the challenge of overlapping conditions, and what patients should expect from a PCAB-accredited compounding pharmacy in 2026.

Understanding Why Commercial Treatments Fail for Chronic Skin Conditions

Mass-produced topicals are built for the average patient, not the individual. They come in fixed concentrations (such as 0.1% triamcinolone), typically feature a single active ingredient, and rely on standardized bases and excipients. That works well enough for a mild, textbook case, but chronic skin disease rarely follows the textbook.

Several structural problems drive treatment failure:

• Irritating excipients. Many commercial products contain preservatives, fragrances, dyes, and propylene glycol that can trigger allergic reactions or actively worsen flares.
• The wrong vehicle. An active ingredient delivered in the wrong base (such as a thin cream applied to a thick psoriatic plaque) may never penetrate effectively, causing failure regardless of the drug’s potency.
• Individual variability. Adverse effects, drug resistance, high costs, and differences in individual response all contribute to a cycle of uncontrolled disease.

The 2025 to 2026 standard of care is shifting toward advanced targeted therapies like biologics, JAK inhibitors, and TYK2 inhibitors. These are meaningful advances, but they are expensive and not universally accessible, leaving a persistent gap. Notably, 76% of psoriasis patients in a national US survey preferred topical therapies, underscoring the ongoing demand for customizable topical solutions that commercial products often cannot deliver.

What Is Compounded Medication for Eczema and Psoriasis?

Compounded medication is a prescription prepared by a licensed compounding pharmacy and customized to an individual patient’s condition, skin type, sensitivities, and treatment history. A licensed healthcare provider, such as a dermatologist or primary care physician, writes the prescription, specifying the ingredients, concentrations, and dosage form.

This differs fundamentally from generic substitution. Compounding is not about copying a commercial product; it is about creating a formulation that does not exist commercially, tailored to a specific patient’s needs. Compounding pharmacies can also recreate discontinued medications or prepare drugs in shortage, ensuring continuity of care.

The market reflects rising demand. The US compounding pharmacy market was valued at roughly $6 to $7 billion in 2025 and is projected to reach between $10.8 and $12.8 billion by 2035. The non-sterile segment, which includes most dermatology topicals, was valued at $4.8 billion in 2025.

The Four Core Advantages of Compounded Dermatology Formulations

Understanding why compounding outperforms commercial options for these specific conditions matters more than simply knowing what it is. The advantages fall into four clinically meaningful categories.

1. Dose Customization Matched to Disease Severity

Corticosteroid concentrations in commercial products are fixed, but disease severity is not. A mild eczema flare and a thick psoriatic plaque require fundamentally different concentrations. Compounding lets the prescriber specify the exact strength needed, reducing both under-treatment (persistent flares) and over-treatment (skin atrophy, systemic absorption). This precision is especially critical for sensitive areas like the face and eyelids, and for pediatric patients who need age- and weight-appropriate concentrations that commercial products do not offer.

2. Combination Therapies in a Single Preparation

One of compounding’s most powerful advantages is blending multiple active ingredients into one formulation. Consider a preparation of Coal Tar 10% / Salicylic Acid 2% / Sulfur 4% / Urea 20% in a single base, targeting inflammation, scale removal, antimicrobial action, and hydration simultaneously. No commercial product offers this combination.

The clinical logic is straightforward: psoriasis and eczema are multifactorial conditions. Addressing only one pathway often produces incomplete results. Combination therapy also reduces the number of products a patient must apply, improving adherence, which is a well-documented challenge in chronic skin disease.

3. Vehicle and Dosage Form Optimization

The vehicle in which an active ingredient is delivered significantly affects penetration, tolerability, and efficacy, yet commercial products offer limited options. Compounding pharmacies can prepare creams, gels, ointments, foams, solutions, sprays, or shampoos matched to the treatment site.

Specific use cases illustrate the point:

• Foams and solutions for scalp psoriasis
• Sprays for skin-fold (intertriginous) areas
• Ointments for thick plaques
• Lightweight gels for facial eczema

The wrong vehicle can cause treatment failure even when the active ingredient is correct, an insight largely absent from most patient-facing content.

4. Elimination of Irritating Excipients

Many patients with eczema or psoriasis have concurrent sensitivities to common excipients: preservatives like parabens and methylisothiazolinone, fragrances, dyes, propylene glycol, and lanolin. Compounding allows a formulation to be built from scratch, using only ingredients the patient can tolerate. This is particularly important for children and those with compromised skin barriers, where excipient-driven irritation is often mistaken for treatment failure.

Key Active Ingredients Used in Compounded Eczema and Psoriasis Formulations

The following ingredients form the backbone of most compounded dermatology formulations.

Corticosteroids at Custom Concentrations

Corticosteroids remain foundational for both conditions. Compounding allows precise concentration adjustment beyond the fixed commercial strengths, enabling step-up or step-down therapy that starts higher during a flare and tapers as skin responds, all without switching products. They can also be combined with penetration enhancers like urea in a single preparation.

Calcineurin Inhibitors: Tacrolimus and Pimecrolimus

These non-steroidal options are especially valuable for sensitive areas like the face, eyelids, and skin folds, where long-term steroid use carries atrophy risk. Compounding permits concentration adjustment and combination with complementary ingredients not possible in commercial formulations, making these ingredients particularly relevant for eczema patients needing long-term maintenance on delicate skin.

Keratolytics: Salicylic Acid, Urea, and Sulfur

• Salicylic acid (0.5 to 10%) softens and removes the thick scale of psoriatic plaques, improving penetration of co-applied anti-inflammatory agents.
• Urea (5 to 40%) acts as both a humectant and, at higher concentrations, a keratolytic; it is critical for the dry, thickened skin of psoriasis and chronic eczema.
• Sulfur provides antimicrobial and keratolytic activity, useful in seborrheic and scalp formulations.

These can be combined at custom concentrations in a single base.

Coal Tar

Coal tar has a long history in psoriasis treatment: it slows abnormal skin cell growth, reduces inflammation, and relieves itch. Commercial coal tar products are limited in concentration and vehicle. Compounding allows higher concentrations incorporated into shampoos, foams, or creams tailored to the treatment site, and can be combined with salicylic acid, sulfur, and urea for comprehensive plaque management.

Ceramides and Moisturizing Bases

Eczema is fundamentally a skin barrier dysfunction disease. Ceramide-enriched bases support barrier repair alongside active anti-inflammatory treatment, delivering both in a single application. The choice of base, whether a petrolatum-based ointment or a ceramide-enriched cream, can be tailored to the patient’s skin type, climate, and preference.

Low Dose Naltrexone (LDN): An Emerging Compounded Option for Psoriasis and Eczema

Low Dose Naltrexone represents one of the most promising and underdiscussed developments in compounded dermatology. Naltrexone is FDA-approved at 50 mg for opioid and alcohol use disorder. At compounded doses of 1 to 5 mg, however, it produces a brief opioid receptor blockade that triggers an upregulation of endogenous opioids and, critically, modulates immune function and decreases inflammatory cytokine activity.

A 2025 clinical review in the Journal of the American Academy of Dermatology documented LDN’s use across multiple inflammatory dermatologic conditions, including psoriasis (JAAD, 2025). The psoriasis data is encouraging: in a prospective study of 71 patients treated with 6 mg LDN for three months, mean PASI scores decreased from 18.47 to 13.51, and in a separate case series, 53% of patients showed marked improvement with 4.5 mg oral LDN.

LDN’s appeal lies in its favorable safety profile: low abuse potential, minimal adverse effects, and low cost compared to biologics. This makes it accessible for patients who cannot tolerate or afford advanced therapies.

It is important to note that LDN is an off-label, compounded medication requiring a prescription. It is not available commercially at therapeutic dermatology doses and must be prepared by a licensed compounding pharmacy. It is also being explored for eczema due to its immune-modulating properties, though the psoriasis evidence is more developed. LDN is not a first-line treatment and should be discussed with a dermatologist as part of a comprehensive plan.

When Eczema and Psoriasis Co-Occur: The Overlap Scenario

Some patients carry diagnoses of both eczema and psoriasis simultaneously, or present with overlapping features of both. While the two conditions share clinical traits (chronic inflammation, barrier dysfunction, and itch), they have distinct immunological drivers: eczema is predominantly Th2-mediated, while psoriasis is predominantly Th1/Th17-mediated.

This creates a genuine treatment dilemma. Commercial products are designed for one condition. A product optimized for psoriasis may worsen the eczema component, and vice versa. Compounding resolves this by targeting multiple inflammatory pathways at once. A single formulation might combine a calcineurin inhibitor (eczema-focused), a keratolytic (psoriasis-focused), and a ceramide-enriched base (barrier repair for both).

The prescriber-pharmacist collaboration at the heart of compounding is uniquely suited to these complex cases. The formulation is built around the patient’s actual presentation, not a diagnostic label. Because patients with overlapping conditions are often the most treatment-resistant and carry the highest quality-of-life burden, personalized compounded therapy is especially valuable for this population.

Compounded Medications for Pediatric Patients with Eczema and Psoriasis

Eczema is predominantly a pediatric condition, affecting up to 20% of children, yet commercial topicals are often formulated for adult skin at adult concentrations. The pediatric compounding advantage addresses this directly: age- and weight-specific concentrations, gentler bases, and elimination of fragrances and preservatives that are especially problematic for children’s sensitive skin.

Pediatric psoriasis, while less common, is a recognized condition. The 2025 FDA approvals included new pediatric psoriasis indications, yet access and tolerability challenges persist. Compounding allows formulations in child-friendly forms such as gentle, fragrance-free creams and ointments. The absence of irritating excipients is particularly critical for children whose skin barrier is already compromised. Nationwide Compounding Rx® offers pediatric compounding capabilities, preparing age-appropriate formulations designed for young, sensitive skin.

Difficult-to-Treat Areas: Scalp, Skin Folds, and Beyond

Certain body locations consistently defeat commercial topicals:

• Scalp psoriasis. Commercial shampoos and solutions are limited in concentration and combination. Compounded foams, solutions, and shampoos can deliver higher concentrations of coal tar, salicylic acid, or corticosteroids in vehicles optimized for the scalp.
• Intertriginous areas (groin, axillae, under-breast). These require lower-potency formulations in non-occlusive vehicles to avoid maceration and increased absorption. Compounding allows precise potency and vehicle selection.
• Facial and eyelid eczema. These demand very low-potency, non-irritating formulations. Compounding can produce tacrolimus or pimecrolimus at appropriate concentrations in gentle, fragrance-free bases.

Notably, the scalp, elbows, and legs were identified as the areas most impactful on quality of life for psoriasis patients, reinforcing the need for site-specific formulation strategies.

Quality and Safety: What to Look for in a Compounding Pharmacy

Trust and safety are legitimate concerns for anyone considering compounded medications. Several markers distinguish quality pharmacies:

• PCAB accreditation. The Pharmacy Compounding Accreditation Board sets rigorous standards that separate quality operations from unaccredited ones.
• USP <795> standards. These govern non-sterile compounding (the framework for most dermatology topicals), covering ingredient quality, testing, and beyond-use dating.
• Independent third-party testing. This verifies potency, sterility where applicable, and consistency. Patients should ask whether a pharmacy performs it.
• API sourcing. High-grade active pharmaceutical ingredients from FDA-inspected and cleared vendors are essential for safety and efficacy.
• Documented stability studies for complex multi-ingredient formulations signal technical rigor.

Nationwide Compounding Rx® is PCAB accredited and USP 800 compliant, performs independent third-party testing, and sources ingredients from FDA-inspected and cleared vendors: concrete quality markers patients and prescribers can rely on.

How the Process Works: From Prescription to Personalized Treatment

Obtaining a compounded medication is more straightforward than many patients expect:

1. Consultation. A dermatologist or prescribing physician evaluates the patient’s condition, treatment history, sensitivities, and goals.
2. Collaboration. The prescriber works with the compounding pharmacy to specify active ingredients, concentrations, vehicle, and dosage form.
3. Preparation. The pharmacy prepares the formulation using quality-verified ingredients, typically within one to two business days.
4. Dispensing. The medication is picked up or shipped nationwide where licensed, with clear usage instructions.

Nationwide Compounding Rx® streamlines this process with dedicated provider and patient portals for prescription submission, order tracking, and refill management. Telehealth integration is also expanding access in 2026, with remote consultations and digital prescription workflows making compounded dermatology treatments more reachable.

On cost: compounded topicals are generally far less expensive than branded biologics like dupilumab, though they are not always covered by insurance. Patients should discuss coverage and out-of-pocket expectations with their prescriber and pharmacy.

Conclusion: Personalized Compounding as a Precision Tool for Chronic Skin Disease

For patients with treatment-resistant eczema, psoriasis, or overlapping conditions, compounded medication is not a fringe alternative. It is a clinically rational, evidence-supported approach that addresses the specific reasons commercial treatments fail: dose customization, combination therapy, vehicle optimization, and excipient elimination.

As biologics and targeted therapies advance, compounding fills the persistent gaps in access, tolerability, and individualization that mass-produced products cannot. Emerging options like LDN, backed by growing JAAD-published evidence, show that the compounding toolkit continues to expand.

The best outcomes come from a collaborative triad: an informed patient, a knowledgeable prescriber, and a quality-accredited compounding pharmacy. For those who have genuinely exhausted standard options, personalized compounding may be the precision approach their condition has needed all along.

Ready to Explore a Compounded Solution for Eczema or Psoriasis?

Nationwide Compounding Rx® is a trusted, PCAB-accredited partner for patients and prescribers seeking personalized dermatology compounding. Key differentiators include PCAB accreditation, USP 800 compliance, independent third-party testing, FDA-cleared ingredient sourcing, one to two business day turnaround, and nationwide shipping where licensed.

Patients are encouraged to speak with their dermatologist or prescribing physician about whether a compounded formulation is appropriate for their condition, and to ask their provider about partnering with Nationwide Compounding Rx®.

Get started today:

• Phone: (480) 499-8379
• Website: nationwidecompounding.com
• Portals: Use the patient or provider portal to submit and manage prescriptions
• Location: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260
• Hours: Monday through Friday, 7:00 AM to 3:30 PM

Every patient relationship follows a simple promise: Connect, Collaborate, Create, Care.